IOVANCE BIOTHERAPEUTICS, INC.

Iovance Biotherapeutics (IOVA) reported zero cyber incidents and zero red-flag 8-K filings in the past 90 days, suggesting operational stability in the recent window. However, low signal in a 90-day window does not equate to low risk; the full SEC analysis Report extends the timeline to 12 months and adds dilution risk scoring, financing history, and AI-detected anomaly signals. The Report also contextualizes any 8-K activity and maps liquidity pressures typical in clinical-stage biotech. The full $49 Report adds 12-month event history, dilution trajectory analysis, and comprehensive risk scoring across capital structure and disclosure patterns.